Author’s response to reviews

Title: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

Authors:

Naohisa Yoshida (naohisa@koto.kpu-m.ac.jp)
Tetsuya Taguchi (ttaguchi@koto.kpu-m.ac.jp)
Masayoshi Nakanishi (mnakan@koto.kpu-m.ac.jp)
Ken Inoue (keninoue71@koto.kpu-m.ac.jp)
Tetsuya Okayama (t-oka@koto.kpu-m.ac.jp)
Takeshi Ishikawa (iskw-t@koto.kpu-m.ac.jp)
Eigo Otsuji (otsuji@koto.kpu-m.ac.jp)
Koichi Takayama (takayama@koto.kpu-m.ac.jp)
Haruo Kuroboshi (rangaku@koto.kpu-m.ac.jp)
Motohiro Kanazawa (motohiro@koto.kpu-m.ac.jp)
Yoshito Itoh (yitoh@koto.kpu-m.ac.jp)

Version: 2 Date: 03 Dec 2018

Author’s response to reviews:

PHAT-D-18-00204R1

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens Naohisa Yoshida; Tetsuya Taguchi; Masayoshi Nakanishi; Ken Inoue; Tetsuya Okayama; Takeshi Ishikawa; Eigo Otsuji; Koichi Takayama; Haruo Kuroboshi; Motohiro Kanazawa; Yoshito Itoh
Dear Dr. Benjamin Ragen,

Editor of BMC Pharmacology and Toxicology

We are very glad to your consideration for the publication of our manuscript for BMC Pharmacology and Toxicology. We changed detail of draft according to peer review’s comments. I would like to receive good news from you.

Sincerely,

Naohisa Yoshida

Department of Molecular Gastroenterology and Hepatology,
Kyoto Prefectural University of Medicine
Graduate School of Medical Science

Editor Comments:

1. Please note that all manuscripts must contain all the following sections under the heading 'Declarations'. The Declarations should follow the Conclusions section, and be before the References.
   • Abbreviations
   • Ethics approval and consent to participate
   • Consent for publication
   • Availability of data and material
   • Competing interests
   • Funding
   • Authors’ contributions
   • Acknowledgements
Please see here for details on the information to be included in these sections:

https://bmcpharmacoltoxicol.biomedcentral.com/submission-guidelines

If the information required is already provided in the main manuscript, please also copy the relevant statements to the Declarations.

If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section.

Answer: Thank you for your comments. I have made the Declarations.

2. Please include the email addresses for all authors on the title page. The corresponding author should still be indicated.

Answer: We included them.

3. As your manuscript describes a retrospective study, not a clinical trial, please remove the sub-section “Registry” from the Abstract.

Answer: We deleted it.

4. Please remove your Abbreviations from the Supplementary files and ensure all Abbreviations are included within your “Declarations” section as detailed above.

Answer: We removed them and included them in the Declarations.

5. Please change the section heading “Introduction” to “Background”.

Answer: Thank you for your comment. We changed it.

6. Please change the section heading “Materials and Methods” to “Methods”.

Answer: We changed it.
7. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Figures (and additional files) should remain uploaded as separate files.

Answer: I have uploaded it.

BMC Pharmacology and Toxicology operates a policy of open peer review, which means that you will be able to see the names of the reviewers who provided the reports via the online peer review system. We encourage you to also view the reports there, via the action links on the left-hand side of the page, to see the names of the reviewers.

Reviewer reports:

Hesham Al-Sallami, PhD (Reviewer 2): I would like to thank the authors of the article titled "Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens" for resubmitting their article and addressing all my comments and suggestions. I have no further comments to make.

Answer: Thank you for your comment.